Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) approved as a less stimulating treatment for ADHD in 2002 (U.S.). The precise mechanism by which it produces its therapeutic effects is unknown, but is thought to be related to its SNRI action.